Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

 Cancer trial: Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Conditions: Advanced Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; ESR1 Gene Mutation

Interventions: Drug: Everolimus; Drug: Elacestrant; Drug: Placebo; Drug: Auxiliary Medicinal Product – Dexamethasone; Drug: Auxiliary Medicinal Product – Luteinizing hormone-releasing hormone (LHRH) analogues

Sponsors: MedSIR; Stemline Therapeutics, Inc.

Not yet recruiting

AI Products for Business or Try Custom Development

AI Sales Bot

Welcome AI Sales Bot, your 24/7 teammate! Engaging customers in natural language across all channels and learning from your materials, it’s a step towards efficient, enriched customer interactions and sales

AI Document Assistant

Unlock insights and drive decisions with our AI Insights Suite. Indexing your documents and data, it provides smart, AI-driven decision support, enhancing your productivity and decision-making.

AI Customer Support

Upgrade your support with our AI Assistant, reducing response times and personalizing interactions by analyzing documents and past engagements. Boost your team and customer satisfaction

AI Scrum Bot

Enhance agile management with our AI Scrum Bot, it helps to organize retrospectives. It answers queries and boosts collaboration and efficiency in your scrum processes.